{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:26:10Z","timestamp":1762953970007,"version":"3.40.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jocn-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jocn.2024.05.025","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:53:51Z","timestamp":1716951231000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)\u2013negative myeloproliferative neoplasms"],"prefix":"10.1016","volume":"125","author":[{"given":"Shirong","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangmei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3727-0114","authenticated-orcid":false,"given":"Yujun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2024.05.025_b0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","article-title":"International consensus classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms","volume":"482","author":"Gianelli","year":"2023","journal-title":"Virchows Arch"},{"issue":"5","key":"10.1016\/j.jocn.2024.05.025_b0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jocn.2024.05.025_b0015","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/ijms25031524","article-title":"Exploring the molecular aspects of Myeloproliferative Neoplasms associated with unusual site vein thrombosis: review of the literature and latest insights","volume":"25","author":"Morsia","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jocn.2024.05.025_b0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-030-20315-3_11","article-title":"Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms","volume":"179","author":"Sankar","year":"2019","journal-title":"Cancer Treat Res"},{"issue":"2","key":"10.1016\/j.jocn.2024.05.025_b0025","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"2","key":"10.1016\/j.jocn.2024.05.025_b0030","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41375-023-02114-5","article-title":"Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification","volume":"38","author":"Pasquer","year":"2024","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.jocn.2024.05.025_b0035","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jocn.2024.05.025_b0040","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s12885-019-5764-4","article-title":"Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000\u20132018","volume":"19","author":"M\u00f3nica","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.jocn.2024.05.025_b0045","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/ijms23031013","article-title":"Insights into the potential mechanisms of JAK2V617F somatic mutation contributing distinct phenotypes in Myeloproliferative Neoplasms","volume":"23","author":"Gou","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.jocn.2024.05.025_b0050","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3390\/cells10081962","article-title":"Integration of molecular information in risk assessment of patients with Myeloproliferative Neoplasms","volume":"10","author":"Loscocco","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jocn.2024.05.025_b0055","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/diagnostics13010163","article-title":"Molecular genetics of thrombotic Myeloproliferative Neoplasms: implications in precision oncology","volume":"13","author":"Chia","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jocn.2024.05.025_b0060","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. In: Bosman FT, Jaffe ES,Lakhani SR, Ohgaki H, editors. World Health Organization classification of tumours. 4th ed. Lyon: IARC; 2008, Chap. 11.270-299367."},{"issue":"8","key":"10.1016\/j.jocn.2024.05.025_b0065","doi-asserted-by":"crossref","first-page":"e2121443","DOI":"10.1001\/jamanetworkopen.2021.21443","article-title":"Trends and regional variation in prevalence of cardiovascular risk factors and association with socioeconomic status in Canada, 2005\u20132016","volume":"4","author":"Dai","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jocn.2024.05.025_b0070","article-title":"Arterial and venous thromboembolic complications in 832 patients with BCR-ABL-negative Myeloproliferative Neoplasms","author":"Wille","year":"2023","journal-title":"Hamostaseologie"},{"issue":"S1","key":"10.1016\/j.jocn.2024.05.025_b0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5045\/br.2023.2023013","article-title":"Novel therapeutic strategies for essential thrombocythemia\/polycythemia vera","volume":"58","author":"Yoon","year":"2023","journal-title":"Blood Res"},{"issue":"4","key":"10.1016\/j.jocn.2024.05.025_b0080","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jocn.2024.05.025_b0085","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jocn.2024.05.025_b0090","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11239-019-02029-y","article-title":"Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms","volume":"49","author":"Seguro","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jocn.2024.05.025_b0095","doi-asserted-by":"crossref","unstructured":"Frederiksen H,Sz\u00e9pligeti S,Bak M, Ghanima W, Hasselbalch HC, Christiansen CF. Vascular diseases in patients with chronicmyeloproliferative neoplasms-impact of comorbidity. Clin Epidemiol 2019; 11:955-67. https:\/\/doi:10.2147\/CLEP.S216787.","DOI":"10.2147\/CLEP.S216787"},{"issue":"6","key":"10.1016\/j.jocn.2024.05.025_b0100","first-page":"1869","article-title":"The risk factors of thrombosis in patients with Philadelphia Chromosome-negative myeloproliferative neoplasms","volume":"29","author":"Zhao","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.jocn.2024.05.025_b0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaccao.2023.03.014","article-title":"Outcomes of patients with Myeloproliferative Neoplasms admitted with myocardial infarction: insights from National Inpatient Sample","volume":"5","author":"Leiva","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jocn.2024.05.025_b0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2023.04.021","article-title":"Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis","volume":"226","author":"Herbreteau","year":"2023","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.jocn.2024.05.025_b0115","doi-asserted-by":"crossref","first-page":"a 034876","DOI":"10.1101\/cshperspect.a034876","article-title":"The molecular genetics of myeloproliferative neoplasms","volume":"10","author":"Marneth","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.jocn.2024.05.025_b0120","first-page":"150","article-title":"The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms","volume":"52","author":"\u015eahin","year":"2021","journal-title":"Turk J Med Sci"},{"issue":"6","key":"10.1016\/j.jocn.2024.05.025_b0125","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/ene.13907","article-title":"Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms","volume":"26","author":"Stefanou","year":"2019","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2024.05.025_b0130","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2V617F-mutated myeloproliferative neoplasms: Risk factors and development of a predictive model","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med"},{"issue":"16","key":"10.1016\/j.jocn.2024.05.025_b0135","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood.2022017697","article-title":"JAK2 V617F allele burden in polycythemia vera: burden of proof","volume":"141","author":"Moliterno","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jocn.2024.05.025_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2022.01.011","article-title":"JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis","volume":"211","author":"Soudet","year":"2022","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.jocn.2024.05.025_b0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jtha.2023.08.028","article-title":"Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms","volume":"22","author":"Guy","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.jocn.2024.05.025_b0150","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/biomedicines11020388","article-title":"Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review","volume":"11","author":"G\u0103man","year":"2023","journal-title":"Review Biomedicines"},{"issue":"2","key":"10.1016\/j.jocn.2024.05.025_b0155","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12185-019-02800-0","article-title":"The role of calreticulin mutations in myeloproliferative neoplasms","volume":"111","author":"Araki","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jocn.2024.05.025_b0160","article-title":"The contemporary approach to CALR-positive myeloproliferative neoplasms","volume":"22(7):3371","author":"BelcicMikic","year":"2021","journal-title":"Int Mol Sci"},{"issue":"436","key":"10.1016\/j.jocn.2024.05.025_b0165","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jocn.2024.05.025_b0170","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3389\/fimmu.2019.01373","article-title":"Platelets as mediators of thromboinflammation in chronic myeloproliferative neoplasms","volume":"10","author":"Marin","year":"2019","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jocn.2024.05.025_b0175","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586824002133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586824002133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T01:04:11Z","timestamp":1717635851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586824002133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":35,"alternative-id":["S0967586824002133"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2024.05.025","relation":{},"ISSN":["0967-5868"],"issn-type":[{"type":"print","value":"0967-5868"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)\u2013negative myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2024.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}